MXPA05012325A - Procedimiento para potenciar la cognicion usando zipirasidona. - Google Patents
Procedimiento para potenciar la cognicion usando zipirasidona.Info
- Publication number
- MXPA05012325A MXPA05012325A MXPA05012325A MXPA05012325A MXPA05012325A MX PA05012325 A MXPA05012325 A MX PA05012325A MX PA05012325 A MXPA05012325 A MX PA05012325A MX PA05012325 A MXPA05012325 A MX PA05012325A MX PA05012325 A MXPA05012325 A MX PA05012325A
- Authority
- MX
- Mexico
- Prior art keywords
- mammal
- formula
- ziprasidone
- compound
- human
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title abstract 4
- 229960000607 ziprasidone Drugs 0.000 title abstract 4
- 230000019771 cognition Effects 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 5
- 206010003805 Autism Diseases 0.000 abstract 2
- 208000020706 Autistic disease Diseases 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 2
- 208000036626 Mental retardation Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000009329 sexual behaviour Effects 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010019191 Head banging Diseases 0.000 abstract 1
- 206010022524 Intentional self-injury Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000005560 Self Mutilation Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 231100000867 compulsive behavior Toxicity 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000004006 stereotypic behavior Effects 0.000 abstract 1
- 208000013623 stereotypic movement disease Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
En un aspecto, la presente invencion, se refiere a un procedimiento de uso de los compuestos piperazinil-heterociclicos de formula I, como se ha definido anteriormente, para potenciar la cognicion en un mamifero, incluyendo un ser humano, por ejemplo un mamifero aquejado de psicosis, autismo, demencia, o retraso mental, que comprende la administracion de una cantidad eficaz de un compuesto de formula I (por ejemplo, ziprasidona) al mamifero; en otro aspecto, la presente invencion se refiere a un procedimiento para reducir o mejorar en un mamifero, incluyendo un ser humano, aquejado de un trastorno o afeccion seleccionado entre autismo, retraso mental, trastorno obsesivo compulsivo, y demencia, los sintomas positivos (por ejemplo, agresion excesiva, conducta sexual desinhibida, conducta sexual inapropiada, agitacion, conducta compulsiva tal como golpearse la cabeza, retorcerse los labios, automutilacion, o conducta estereotipica) asociados a los trastornos o afecciones anteriormente mencionados, dicho procedimiento comprende la administracion de una cantidad eficaz de un compuesto de formula I (por ejemplo, ziprasidona) al mamifero; en otro aspecto, la presente invencion se refiere a un procedimiento para tratar el trastorno bipolar pediatrico en un mamifero, incluyendo un ser humano, dicho procedimiento comprende la administracion de una cantidad eficaz de un compuesto de formula I (por ejemplo, ziprasidona) al mamifero; los compuestos de la formula I se definen como sigue (ver formula): o una sal de adicion de acidos farmaceuticamente aceptable del mismo, en la que Ar, n, X e Y son como se han definido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47137903P | 2003-05-16 | 2003-05-16 | |
| PCT/IB2004/001600 WO2004100956A1 (en) | 2003-05-16 | 2004-05-05 | Method for enhancing cognition using ziprasidone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05012325A true MXPA05012325A (es) | 2006-01-30 |
Family
ID=33452442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05012325A MXPA05012325A (es) | 2003-05-16 | 2004-05-05 | Procedimiento para potenciar la cognicion usando zipirasidona. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20050014764A1 (es) |
| EP (1) | EP1626722A1 (es) |
| JP (1) | JP2006528236A (es) |
| AR (1) | AR044337A1 (es) |
| BR (1) | BRPI0419067A (es) |
| CA (2) | CA2525323A1 (es) |
| MX (1) | MXPA05012325A (es) |
| TW (1) | TW200507847A (es) |
| WO (1) | WO2004100956A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2036547A3 (en) | 2001-07-20 | 2009-12-23 | Psychogenics Inc. | Treatment for Attention-Deficit Hyperactivity Disorder |
| PT2316456T (pt) | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
| AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| MY158766A (en) * | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| DK2135603T3 (da) | 2005-11-22 | 2013-03-25 | Orexigen Therapeutics Inc | Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet |
| JP2009524637A (ja) * | 2006-01-27 | 2009-07-02 | ファイザー・プロダクツ・インク | アミノフタラジン誘導体化合物 |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| MX2009003874A (es) * | 2006-10-12 | 2009-04-22 | Xenon Pharmaceuticals Inc | Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos. |
| TW200825091A (en) * | 2006-10-12 | 2008-06-16 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds useful in treating sodium channel-mediated diseases or conditions |
| JP5460324B2 (ja) * | 2006-10-12 | 2014-04-02 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 治療剤としてのスピロ−オキシインドール化合物の使用 |
| AU2007319472B2 (en) | 2006-11-09 | 2013-01-17 | Nalpropion Pharmaceuticals Llc | Methods Of Administering Weight Loss Medications |
| CN103058957A (zh) | 2007-06-29 | 2013-04-24 | 埃莫里大学 | 用于神经保护的nmda受体拮抗剂 |
| EP2296658A4 (en) * | 2008-05-09 | 2014-01-15 | Univ Emory | ANTAGONISTS OF NMDA RECEPTORS USEFUL FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS |
| US20110144145A1 (en) | 2008-05-30 | 2011-06-16 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| RU2011119626A (ru) | 2008-10-17 | 2012-11-27 | Ксенон Фармасьютикалз Инк. | Спирооксиндольные соединения и их применение в качестве терапевтичеких средств |
| CA2741024A1 (en) * | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| MY165579A (en) * | 2009-10-14 | 2018-04-05 | Xenon Pharmaceuticals Inc | Synthetic methods for spiro-oxindole compounds |
| AU2011203867B2 (en) | 2010-01-11 | 2015-12-03 | Nalpropion Pharmaceuticals Llc | Methods of providing weight loss therapy in patients with major depression |
| US9504671B2 (en) | 2010-02-26 | 2016-11-29 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| CN102958927A (zh) | 2010-05-12 | 2013-03-06 | Abbvie公司 | 激酶的吲唑抑制剂 |
| EP2858640B1 (en) | 2012-06-06 | 2020-03-25 | Nalpropion Pharmaceuticals LLC | Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk |
| CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| WO2016191316A1 (en) * | 2015-05-22 | 2016-12-01 | Stem Cell Theranostics, Inc. | Modulation of drug-induced cardiotoxicity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| AU730856C (en) * | 1996-05-07 | 2001-11-15 | Pfizer Inc. | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol- 3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)- indol-2-one(=ziprasidone),it's preparation and it's use as dopamine D2 antagonist |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| IL125951A (en) * | 1997-09-05 | 2003-09-17 | Pfizer Prod Inc | A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| US6387904B2 (en) * | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
| WO2000059459A1 (en) * | 1999-03-30 | 2000-10-12 | Lion Corporation | Hairdye composition of single preparation type containing an oxidase |
| EP1165083A2 (en) * | 1999-04-06 | 2002-01-02 | Sepracor Inc. | Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
-
2004
- 2004-05-05 WO PCT/IB2004/001600 patent/WO2004100956A1/en active Application Filing
- 2004-05-05 BR BRPI0419067-0A patent/BRPI0419067A/pt not_active IP Right Cessation
- 2004-05-05 JP JP2006530660A patent/JP2006528236A/ja active Pending
- 2004-05-05 CA CA002525323A patent/CA2525323A1/en not_active Abandoned
- 2004-05-05 CA CA002625837A patent/CA2625837A1/en not_active Abandoned
- 2004-05-05 EP EP04731234A patent/EP1626722A1/en not_active Withdrawn
- 2004-05-05 MX MXPA05012325A patent/MXPA05012325A/es unknown
- 2004-05-14 TW TW093113727A patent/TW200507847A/zh unknown
- 2004-05-14 AR ARP040101652A patent/AR044337A1/es unknown
- 2004-05-14 US US10/846,797 patent/US20050014764A1/en not_active Abandoned
-
2008
- 2008-04-28 US US12/110,522 patent/US20080269246A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1626722A1 (en) | 2006-02-22 |
| JP2006528236A (ja) | 2006-12-14 |
| WO2004100956A1 (en) | 2004-11-25 |
| AR044337A1 (es) | 2005-09-07 |
| CA2525323A1 (en) | 2004-11-25 |
| BRPI0419067A (pt) | 2007-12-11 |
| US20080269246A1 (en) | 2008-10-30 |
| TW200507847A (en) | 2005-03-01 |
| CA2625837A1 (en) | 2004-11-25 |
| US20050014764A1 (en) | 2005-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200507847A (en) | Method for enhancing cognition using ziprasidone | |
| BRPI0512220A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
| MA34922B1 (fr) | Imidazo[5,1-f][1,2,4] triazines pour le traitement de troubles neurologiques | |
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| US10493069B2 (en) | Methods of treating behavioral syndromes using pipradrol | |
| MX2009012163A (es) | Hetarilanilinas como moduladores para beta-amiloide. | |
| MA30411B1 (fr) | Derives de triazolopyrazine utiles comme agent anticancereux | |
| DE602005004286D1 (de) | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs | |
| AU2003256755A8 (en) | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations | |
| MY140525A (en) | Pharmaceutical uses for alpha2delta ligands | |
| TW200639159A (en) | Treatment of pain | |
| UA88792C2 (ru) | Гидроксибензоатные соли метаникотиновых соединений | |
| MA30592B1 (fr) | Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques | |
| WO2001078704A3 (en) | Gaba substrate and the use thereof for treating cognitive and emotional disorders | |
| TW200602297A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
| MX2009005351A (es) | Compuestos utiles para tratar trastornos neurodegenerativos. | |
| TW200509929A (en) | Treatment of bipolar disorders and associated symptoms | |
| MX2022011179A (es) | Uso medico de daridorexant. | |
| Devaraj et al. | Interaction between warfarin and topical miconazole cream | |
| WO2008018639A3 (en) | Glycine transporter inhibitor | |
| GB2426517A (en) | Methods and agents for inhibiting dynamin-dependent endocytosis | |
| TW200504036A (en) | Novel lactams and uses thereof | |
| CA2716966A1 (en) | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | |
| WO2001080845A3 (en) | (2-aminoethyl) oxime derivatives for the treatment of depression | |
| MX2013000079A (es) | Tratamiento con l-metilfolato para desordenes psiquiatricos o neurologicos. |